Mainz Biomed N.V (NASDAQ:MYNZ) does about 181.88K shares in volume on a normal day but saw 1164189 shares change hands in the recent trading day. The company now has a market cap of 7.56M USD. Its current market price is $1.98, marking an increase of 7.03% compared to the previous close of $1.85. The 52 week high reached by this stock is $19.00 whilst the lowest price level in 52 weeks is $1.34.
Mainz Biomed N.V (MYNZ) has a 20-day trading average at $1.5670 and the current price is -89.58% off the 52-week high compared with 47.97% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.9579 and its 200-day simple moving average is $5.4198. If we look at the stock’s price movements over the week, volatility stands at 18.41%, which decreases to 10.28% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 59.30 to suggest the stock is neutral.
The consensus objective for the share price is $14.00, suggesting that the stock has a potential upside of 85.86% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 14, 2025 when Maxim Group initiated the stock to “Buy” and issued a price target of $14.
The current price level is 26.36%, 1.13%, and -63.47% away from its SMA20, SMA50, and SMA200 respectively, with the MYNZ price moving above the 50-day SMA on current market day. Mainz Biomed N.V (MYNZ) stock is up 36.55% over the week and -0.50% over the past month. Its price is -89.32% year-to-date and -54.17% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 85.86 percent from here.
Outstanding shares total 3.81M with insiders holding 1.95% of the shares and institutional holders owning 6.13% of the company’s common stock. The beta has a value of 0.22.
